Ian Anderson 6 p.m., March 7
Could Amylin Be Takeover Target?
Biotech Amylin stock is up 18.04% to $14.33 at mid-day Monday (Jan. 30), following Food & Drug Administration approval for U.S. marketing of Bydureon, a once-weekly version of Amylin's diabetes shot.
This was the third try with the FDA. Amylin is working with Alkermes on the drug.
Now, takeover sharks may be circling Amylin, according to Bloomberg News. Those rumors may also be boosting the stock.